公开(公告)号：US20150160238A1

公开(公告)日：2015-06-11

申请号：US14235513

申请日：2012-07-27

Applicant: Metanomics GmbH ,  metanomics GmbH ,  Ruprecht-Karls-Univeristät Heidelberg

Inventor： Regina Reszka ,  Jens Fuhrmann ,  Jürgen Kastler ,  Bianca Bethan ,  Martin Kluttig ,  Hugo A. Katus ,  Norbert Frey ,  Johanna Wolf ,  Tanja Weis

IPC: G01N33/68 ,  G01N33/74 ,  G01N33/62 ,  G01N33/92 ,  G01N33/50

CPC classification number: G01N33/6893 ,  G01N30/72 ,  G01N30/8668 ,  G01N33/50 ,  G01N33/62 ,  G01N33/6806 ,  G01N33/743 ,  G01N33/92 ,  G01N2030/3076 ,  G01N2030/8813 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2560/00 ,  G01N2800/325 ,  G01N2800/56 ,  Y10T436/143333 ,  Y10T436/144444 ,  Y10T436/145555 ,  Y10T436/146666 ,  Y10T436/147777 ,  Y10T436/148888 ,  Y10T436/163333 ,  Y10T436/171538 ,  Y10T436/173845 ,  Y10T436/200833 ,  Y10T436/201666 ,  Y10T436/203332 ,  Y10T436/21

Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject and a method for monitoring progression or regression of heart failure in a subject. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Abstract translation: 本发明涉及诊断方法领域。 具体地，本发明考虑了用于诊断受试者的心力衰竭的方法和用于监测受试者的心力衰竭进展或消退的方法。 本发明还涉及用于执行上述方法的工具，例如诊断装置。

公开(公告)号：US10393762B2

公开(公告)日：2019-08-27

申请号：US15012449

申请日：2016-02-01

Applicant: METANOMICS GMBH ,  Ruprecht-Karls-Universität Heidelberg

Inventor： Jens Fuhrmann ,  Regina Reszka ,  Juergen Kastler ,  Kristina Busch ,  Edgar Leibold ,  Hugo Katus ,  Norbert Frey ,  Johanna Sigl ,  Tanja Weis

IPC: G01N33/92 ,  G01N33/48 ,  G01N33/64 ,  G01N33/68 ,  A61B5/02 ,  A61B5/145

Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject, a method for identifying whether a subject is in need for a therapy of heart failure or a method for determining whether a heart failure therapy is successful. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

公开(公告)号：US20170285049A1

公开(公告)日：2017-10-05

申请号：US15507801

申请日：2015-09-01

Applicant: METANOMICS GMBH ,  Ruprecht-Karls-Universität Heidelberg

Inventor： Philipp Schatz ,  Henning Witt ,  Martin Dostler ,  Susan Carvalho ,  Erik Peter ,  Philipp Ternes ,  Philipp Mappes ,  Hans Dirk ,  Tobias Daniel ,  Elvis Tahirovic ,  Hugo Katus ,  Norbert Frey ,  Tanja Weis

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N33/6893 ,  G01N2405/00 ,  G01N2405/02 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2800/325

Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject based on determining the amounts of at least three biomarkers. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

公开(公告)号：US20170212135A1

公开(公告)日：2017-07-27

申请号：US15329669

申请日：2015-07-28

Applicant: Metanomics GMBH ,  Ruprecht-Karls-Universität Heidelberg

Inventor： Philipp Schatz ,  Henning Witt ,  Erik Peter ,  Philipp Ternes ,  Philipp Mappes ,  Hogo A. Katus ,  Tanja Weis ,  Norbert Frey ,  Hans Dirk Duengen ,  Tobias Daniel Trippel ,  Elvis Tahirovic

IPC: G01N33/92 ,  C12Q1/60

CPC classification number: G01N33/92 ,  C12Q1/60 ,  G01N33/502 ,  G01N2405/08 ,  G01N2800/325

Abstract: The present invention relates to diagnostic means and methods for heart failure. In particular, the invention relates to a method for diagnosing heart failure in a subject suspected to suffer therefrom comprising determining the amount of at least one cholesterol parameter and/or total sphingomyelins and/or triacylglycerols in a sample of the said subject, and comparing the amount(s) determined in step (a) to a reference, whereby it is diagnosed whether the subject suffers from heart failure, or not. Moreover, the invention pertains to a device for diagnosing whether a subject suffers from heart failure, or not, and to the use, in general, of enzymatic detection agents for at least one cholesterol parameter and/or total sphingomyelins and/or triacylglycerols for diagnosing in a sample of a subject whether the said subject suffers from heart failure, or not. Finally, contemplated is a kit for diagnosing heart failure in subject suspected to suffer therefrom.

公开(公告)号：US20190064191A1

公开(公告)日：2019-02-28

申请号：US16075348

申请日：2017-02-03

Applicant: METANOMICS GMBH ,  RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Inventor： Philipp SCHATZ ,  Henning WITT ,  Erik PETER ,  Martin DOSTLER ,  Susan CARVALHO ,  Philipp TERNES ,  Philipp MAPPES ,  Jenny J. FISCHER ,  Hugo KATUS ,  Tanja WEIS ,  Norbert FREY

IPC: G01N33/92

Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for differentiating in a subject between heart failure and pulmonary disease based on determining the amounts of at least one biomarker. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

公开(公告)号：US20160047829A1

公开(公告)日：2016-02-18

申请号：US14435952

申请日：2013-10-16

Applicant: METANOMICS GMBH ,  REPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

Inventor： Jens Fuhrmann ,  Jenny Fischer ,  Regina Reszka ,  Hugo A Katus ,  Nobert Frey ,  Johanna Sigl ,  Tanja Weis

IPC: G01N33/92 ,  G01N33/64 ,  G01N33/50 ,  G01N33/62

CPC classification number: G01N33/92 ,  G01N33/50 ,  G01N33/62 ,  G01N33/64 ,  G01N33/6896 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2560/00 ,  G01N2800/02 ,  G01N2800/042 ,  G01N2800/2814 ,  G01N2800/32 ,  G01N2800/325 ,  G01N2800/347

Abstract: The present invention relates to a method for determining a clearance normalized amount of a metabolite disease biomarker in a sample including the steps of (a) determining the amount of the disease biomarker in at least a first type of sample of a subject suspected to suffer from the disease, (b) determining the amount of a kidney function biomarker which correlates with the glomerular filtration rate (GFR) in the said at least first type of sample, and (c) determining a clearance normalized amount for the metabolite disease biomarker by normalizing the amount determined for the metabolite disease biomarker in step (a) to the amount of the kidney function biomarker determined in step (b). Moreover, the invention also relates to a method for diagnosing a disease in a subject suspected to suffer therefrom and to a device for determining a clearance normalized amount of a metabolite disease biomarker in a sample.

Abstract translation: 本发明涉及一种用于确定样品中代谢物疾病生物标志物的清除标准化量的方法，包括以下步骤：（a）确定怀疑患有至少一种受试者的至少第一类样品的疾病生物标志物的量 所述疾病，（b）确定与所述至少第一类型样品中的肾小球滤过率（GFR）相关的肾功能生物标志物的量，和（c）通过归一化来测定代谢物疾病生物标志物的清除标准化量 在步骤（a）中为代谢物疾病生物标志物确定的量与步骤（b）中测定的肾功能生物标志物的量的量。 此外，本发明还涉及用于诊断疑似受试者的疾病的方法以及用于测定样品中代谢物疾病生物标志物的清除标准化量的装置。

公开(公告)号：US20180238914A1

公开(公告)日：2018-08-23

申请号：US15753388

申请日：2016-08-19

Applicant: METANOMICS GMBH ,  RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

Inventor： Philipp Schatz ,  Henning Witt ,  Erik Peter ,  Martin Dostler ,  Susan Carvalho ,  Philipp Ternes ,  Philipp Mappes ,  Jenny Fischer ,  Hugo A. Katus ,  Tanja Weis ,  Norbert Frey

IPC: G01N33/92 ,  G01N33/68

Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing a cardiac disease in a subject based on determining the amounts of at least three lipid metabolite biomarkers and at least one further cardiac biomarker. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

公开(公告)号：US20140030744A1

公开(公告)日：2014-01-30

申请号：US14041432

申请日：2013-09-30

Applicant: INSERM Institute National de la Sante et de la Recherche Medicale ,  Metanomics GmbH

Inventor： Jens Fuhrmann ,  Dietrich Rein ,  Beate Kamlage ,  Jan C. Wiemer ,  Michael Manfred Herold ,  Karine Clément ,  David M. Mutch

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/5023 ,  G01N2800/042 ,  G01N2800/044

Abstract: The present invention relates to the field of diagnostic measures. Specifically, it contemplates a method for assessing whether gastric bypass therapy was successful in a subject, a method of predicting whether gastric bypass therapy will be beneficial for a subject in need thereof, and a method of diagnosing whether a supportive therapy accompanying gastric bypass has beneficial effects on a subject in need thereof. Further provided are diagnostic methods for diabetes and body lean mass. Furthermore, the invention relates to a method for identifying a treatment against diabetes and/or obesity.

Abstract translation: 本发明涉及诊断措施领域。 具体地，本发明涉及一种用于评估胃旁路治疗是否成功的方法，预测胃旁路治疗是否有益于有需要的受试者的方法，以及诊断伴随胃旁路的支持治疗是否具有益处的方法 对有需要的受试者的影响。 还提供了糖尿病和身体瘦体重的诊断方法。 此外，本发明涉及鉴定抗糖尿病和/或肥胖症的治疗方法。

公开(公告)号：US20160209433A1

公开(公告)日：2016-07-21

申请号：US14914815

申请日：2014-09-01

Applicant: METANOMICS GMBH ,  RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

Inventor： Henning Witt ,  Juergen Kastler ,  Bianca Bethan ,  Erik Peter ,  Philipp Schatz ,  Hans Dirk Duengen ,  Tobias Daniel Trippel ,  Elvis Tahirovic ,  Hugo A. Katus ,  Norbert Frey ,  Tanja Weis

IPC: G01N33/92 ,  G06F19/28

CPC classification number: G01N33/92 ,  G01N33/6893 ,  G01N2405/08 ,  G01N2560/00 ,  G01N2570/00 ,  G01N2800/325 ,  G16B50/00

Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject based on a group of biomarkers. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Abstract translation: 本发明涉及诊断方法领域。 具体地，本发明考虑了一种用于基于一组生物标志物来诊断受试者的心力衰竭的方法。 本发明还涉及用于执行上述方法的工具，例如诊断装置。